Christoph Henkenberens

List of Publications by Year
in descending order

41	1,065	361413	434195
papers	citations	20 h-index	31 g-index

42	42	42	1682
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1962-1968.	5.0	120
2	68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. European Radiology, 2016, 26, 4345-4353.	4.5	73
3	Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 960-968.	6.4	70
4	68Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer. Strahlentherapie Und Onkologie, 2016, 192, 431-439.	2.0	56
5	Patterns of Progression After 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 103, 95-104.	0.8	53
6	Multiple Time-Point 68Ga-PSMA I&T PET/CT for Characterization of Primary Prostate Cancer. Clinical Nuclear Medicine, 2017, 42, e286-e293.	1.3	49
7	68Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer. Nuclear Medicine and Molecular Imaging, 2017, 51, 314-322.	1.0	44
8	Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. Radiotherapy and Oncology, 2019, 141, 208-213.	0.6	42
9	PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 913-922.	6.4	34
10	Prostate-specific Membrane Antigen Positron Emission Tomographyâ€“detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. European Urology Focus, 2021, 7, 309-316.	3.1	34
11	Late radiation side effects, cosmetic outcomes and pain in breast cancer patients after breast-conserving surgery and three-dimensional conformal radiotherapy. Strahlentherapie Und Onkologie, 2016, 192, 8-16.	2.0	33
12	Frequency and risk factors for arm lymphedema after multimodal breast-conserving treatment of nodal positive breast Cancer â€“ a long-term observation. Radiation Oncology, 2019, 14, 39.	2.7	33
13	Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network. Journal of Nuclear Medicine, 2021, 62, 823-828.	5.0	32
14	Inhalative steroids as an individual treatment in symptomatic lung cancer patients with radiation pneumonitis grade II after radiotherapy â€“ a single-centre experience. Radiation Oncology, 2016, 11, 12.	2.7	31
15	Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stageÂIII non-small cell lung cancer. Strahlentherapie Und Onkologie, 2018, 194, 79-90.	2.0	30
16	Local recurrence of breast cancer: conventionally fractionated partial external beam re-irradiation with curative intention. Strahlentherapie Und Onkologie, 2018, 194, 806-814.	2.0	28
17	A novel openâ€source softwareâ€based highâ€precision workflow for target definition in cardiac radioablation. Journal of Cardiovascular Electrophysiology, 2020, 31, 2689-2695.	1.7	28
18	Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study. Journal of Nuclear Medicine, 2020, 61, 1602-1606.	5.0	25

#	Article	IF	Citations
19	68Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy. Anticancer Research, 2017, 37, 1273-1280.	1.1	25
20	Patterns of relapse as determined by 68Ga-PSMA ligand PET/CT after radical prostatectomy. Strahlentherapie Und Onkologie, 2018, 194, 303-310.	2.0	23
21	Influence of shortâ€term dexamethasone on the efficacy of ¹⁷⁷Luâ€PSMAâ€617 in patients with metastatic castrationâ€resistant prostate cancer. Prostate, 2020, 80, 619-631.	2.3	20
22	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. BMC Cancer, 2020, 20, 362.	2.6	20
23	Comparison of 68â€¯Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer. Strahlentherapie Und Onkologie, 2019, 195, 420-429.	2.0	19
24	Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapyâ€”a multicenter retrospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1852-1863.	6.4	16
25	Value of PET imaging for radiation therapy. Strahlentherapie Und Onkologie, 2021, 197, 1-23.	2.0	16
26	Volumetric 68Ga-DOTA-TATE PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with metastatic gastroenteropancreatic neuroendocrine tumors. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 66, .	0.7	14
27	Comorbidity indexing for prediction of the clinical outcome after stereotactic body radiation therapy in non-small cell lung cancer. Radiation Oncology, 2018, 13, 213.	2.7	13
28	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2328-2338.	6.4	13
29	Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy. Diagnostics, 2021, 11, 504.	2.6	12
30	Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancerâ€”results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group. Strahlentherapie Und Onkologie, 2021, 197, 385-395.	2.0	9
31	Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy. Strahlentherapie Und Onkologie, 2020, 196, 1006-1017.	2.0	8
32	Reduced radiation dose for elective nodal irradiation in node-negative anal cancer: back to the roots?. Strahlentherapie Und Onkologie, 2015, 191, 845-854.	2.0	7
33	Comparison of relative and absolute rectal doseâ€“volume parameters and clinical correlation with acute and late radiation proctitis in prostate cancer patients. Strahlentherapie Und Onkologie, 2019, 195, 103-112.	2.0	7
34	Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer. Frontiers in Oncology, 2021, 11, 664225.	2.8	7
35	Temporal and spatial dose distribution of radiation pneumonitis after concurrent radiochemotherapy in stage III non-small cell cancer patients. Radiation Oncology, 2017, 12, 165.	2.7	5
36	Assessment of Î³-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors. Cancers, 2021, 13, 1516.	3.7	5

#	Article	IF	Citations
37	Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy. World Journal of Urology, 2016, 34, 1239-1245.	2.2	3
38	Clinical Value of Squamous Cell Carcinoma Antigen (SCCAg) in Anal Cancer - A Single-Center Retrospective Analysis. Anticancer Research, 2016, 36, 3173-7.	1.1	3
39	The Prognostic Value of Irradiated Lung Volumes on the Prediction of Intra-/ Post-Operative Mortality in Patients after Neoadjuvant Radiochemotherapy for Esophageal Cancer. A Retrospective Multicenter Study.. Journal of Cancer, 2015, 6, 254-260.	2.5	2
40	Value of PET imaging for radiation therapy. Nuklearmedizin - NuclearMedicine, 2021, 60, 326-343.	0.7	2
41	A new era of thoracic oncology? Ex-vivo stereotactic ablative radiosurgery within Ex-vivo Lung Treatment System as a hybrid therapy for unresectable locally advanced pulmonary malignancies. Medical Hypotheses, 2016, 92, 31-34.	1.5	0